Over 1,200 Xarelto lawsuits are pending in a multidistrict litigation in the U.S. District Court for the Eastern District of Louisiana. Xarelto plaintiffs allege that the anticoagulant drug’s manufacturers, including Bayer HealthCare Pharmaceuticals and Johnson & Johnson’s Janssen Pharmaceutical, did not provide patients and doctors with adequate warning about Xarelto’s severe bleeding risks.
Approved by the U.S. Food and Drug Administration (FDA) in ...
continue reading...
Janssen Pharmaceuticals and Bayer have long insisted their blood-thinning drug Xarelto is a safer, more reliable alternative to the decades-old warfarin. However, a new study recently published in the American Heart Association’s journal Circulation suggests the popular “new-age” anticoagulant may be no safer than warfarin in terms of bleeding in elderly patients.
Xarelto was approved by the U.S. Food and Drug Administration in 2011 ...
continue reading...In a column in the Spokesman-Review out of Washington, Dr. Anthony L. Komaroff, M.D., answers a letter-writer’s question about the blood-thinner Pradaxa.
The letter-writer says his wife has atrial fibrillation, and her medication was recently changed from warfarin to Pradaxa. He wants to know if she’s right in claiming that the medicine is just as effective, although it requires fewer tests.
Komaroff writes that technically, Pradaxa is just as effective in preventing blood clots. But Pradaxa presents some risks that warfarin, the ...
continue reading...
A report on the blog FiercePharma says the approval of blood thinner Eliquis in Europe has the manufacturers of competing medications “on their toes.”
Eliquis, from Pfizer and Bristol-Myers Squibb, was developed as an alternative to warfarin, which for decades has been the standard treatment for blood clot prevention.
But according to FiercePharma, warfarin “comes with a host of dosage-tweaking rules, plus interactions with alcohol and food, so it is difficult ...
continue reading...The U.S. Food and Drug Administration has approved a new blood thinner manufactured by Pfizer Inc. and Bristol-Myers Squibb. A Bloomberg report describes Eliquis as a “potential blockbuster heart drug.”
The Food and Drug Administration cleared Eliquis for the prevention of blood clots that develop in patients with the heart rhythm disorder atrial fibrillation, after the manufacturers failed in two previous efforts to win approval for the drug.
It’s among a ...
continue reading...Regulators in Japan have approved the blood thinner Eliquis, the Japan Daily Times reports.
Eliquis is the brand name for apixaban, manufactured by Bristol-Myers Squibb Co and Pfizer Inc. It’s among a new class of blood thinners meant to replace decades-old warfarin, which is effective but can be difficult to use because it requires dietary restrictions and frequent testing.
Pharmaceutical companies have been looking to warfarin alternatives as potentially profitable areas ...
continue reading...
